Key facts
- This page summarizes Sameer Dewan's Form 3 filing for Genpact LTD (G).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2024, 16:53.
Sameer Dewan - 29 Feb 2024 Form 3 Insider Report for Genpact LTD (G)
- Reporting relationship
- Senior Vice President
- Issuer ticker
- G
- Reported as of
- 29 Feb 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 11 Mar 2024, 16:53:22 UTC
- Next SEC filing
- 15 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas D. Scholtes, as Attorney-in-fact for Sameer Dewan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sameer Dewan filed Form 3 for Genpact LTD (G) on 11 Mar 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
G
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 54,875
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
G
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 42,880
- Exercise price
- $44.90
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes (i) 4,584 unvested restricted share units (RSUs) granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan (the "Plan"), of which 50% will vest on January 10, 2025 and the remaining 50% will vest on January 10, 2026, subject to the reporting person's continued service through each vesting date, (ii) 12,174 shares underlying performance share units (PSUs) granted under the Plan on March 20, 2022, and (iii) 1,654 shares acquired under the Genpact Employee Stock Purchase Plan. The PSU grant was subject to performance conditions which have been satisfied, and each PSU and RSU represents the contingent right to receive one common share. The 2022 PSU grant will vest on January 10, 2025, subject to the reporting person's continued service through such date.
Footnote F2
The option vested 50% on January 10, 2024 and the remaining 50% vests on January 10, 2026, subject to the reporting person's continued service through such date.
SEC remarks
Exhibit 24.1 - Power of Attorney